CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
← catalyst calendarSponsored by Ocular Therapeutix, Inc. (industry) · OCUL — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
19actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-03
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-04-25 | actual | When the study began enrolling |
| Primary completion | 2021-05-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2021-05-24 | actual | The whole study's end, after follow-up |
| First posted | 2020-04-24 | actual | When this record first appeared on the registry |
| Results posted | 2024-10-01 | actual | When the sponsor posted results to the registry |
| Record updated | 2024-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ocular Hypertension
- Open Angle Glaucoma
Intervention
- Drug: OTX-TIC
Primary outcomes
what the primary-completion date above is the date OFOcular Treatment Emergent Adverse Events
measured Through study completion, 6 months
Efficacy Outcome
measured Diurnal IOP [12 Week Visit]
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2020-07-28 · 1.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2020-07-28 · 510 KB · SAP_001.pdf
Related
OCUL · their whole pipeline · Glaucoma readouts
OCUL's other studiesmost recently updated first
- A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) Phase 2 · Completed
- Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study Phase 3 · Recruiting
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy Phase 3 · Recruiting
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration Phase 3 · Active, not recruiting
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration Phase 3 · Active, not recruiting
Permalink · OCUL's whole pipeline · Catalyst calendar · Every registered study · What changed